Screening for Factor V. Leiden mutation (FVL) in users of combined oral contraceptives (COC) or hormone replacement therapy (HRT);Vyšetřování leidenské mutace (FVL - Leidenská mutace faktoru V) u žen v souvislosti s užíváním kombinované hormonální kontracepce nebo hormonální substitučni léčby

Ceska Gynekologie

Volumn 68, Issue 3, 2003, Pages 167-174

  Cibula, David ^a   Unzeitig, V ^b   Zivny J ^a  

^a CHARLES UNIVERSITY   (Czech Republic)

^b UNIVERSITY HOSPITAL BRNO   (Czech Republic)

Author keywords

Combined oral contraceptives; Factor V Leiden mutation; Hereditary thrombophilias; Hormone replacement therapy; Thromboembolic disease

Indexed keywords

BLOOD CLOTTING FACTOR 5 LEIDEN; ORAL CONTRACEPTIVE AGENT; BLOOD CLOTTING FACTOR 5;

CZECH REPUBLIC; DEEP VEIN THROMBOSIS; FAMILY HISTORY; FEMALE; GENE MUTATION; GENETIC SCREENING; HIGH RISK POPULATION; HORMONE SUBSTITUTION; HUMAN; LUNG EMBOLISM; REVIEW; THROMBOEMBOLISM; ESTROGEN THERAPY; GENETIC MARKER; GENETIC PREDISPOSITION; GENETICS; POINT MUTATION; RISK FACTOR; THROMBOPHILIA;

CONTRACEPTIVES, ORAL, COMBINED; CONTRACEPTIVES, ORAL, HORMONAL; ESTROGEN REPLACEMENT THERAPY; FACTOR V; FEMALE; GENETIC MARKERS; GENETIC PREDISPOSITION TO DISEASE; HUMANS; POINT MUTATION; RISK FACTORS; THROMBOPHILIA;

EID: 0038006658     PISSN: 12107832     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (40)

1. Altés, A., Souto, J. C., Mateo, J., Borrell, M., Fontcuberta, J.: Activated protein C resistance assay when applied in the general population. Am. J. Obstet. Gynec., 176, 1997, s. 358-359.
2. Anderson, F. A., Wheeler, H. B., Goldberg, R. J. et al.: A population-based perspective of the hospital incidence and case-fatality rates of deep vein thrombosis and pulmonary embolism. Arch. Intern. Med., 151, 1991, s. 933-938.
3. Bloemenkamp, K. W. M., Rosendaal, F. R., Buller, H. R., Helmerhorst, F. M., Colly, L. P., Vandenbroucke, J. P.: Risk of venous thrombosis with use of current low-dose oral contraceptives is not explained by diagnostic suspicion and referral bias. Arch. Int. Med., 159, 1999, s. 65-70.
4. Bloemenkamp, K. W. M., Rosendaal, F. R., Helmerhorst, F. M., Buller, H. R., Vandenbroucke, J. P.: Enhancement by factor V Leiden mutation of risk of deep-vein thrombosis associated with oral contraceptives containing a third-generation progestagen. Lancet, 346, 1995, s. 1593-1596.
5. Cosmi, B., Legnani, C., Bernardi, F., Cocheri, S., Palareti, G.: Value of family history in identifying women at risk of venous thromboembolism during oral contraception: observational study. BMJ, 322, 2001, s. 1024-1025.
6. Creinin, M. D., Lisman, R., Strickler, R. C.: Screening for factor V Leiden mutation before prescribing combination oral contraceptives. Fertil. Steril., 72, 1999, s. 646-651.
7. Daly, E., Vessey, M. P., Hawkins, M. M., Carson, J. L., Gouogh, P., Marsh, S.: Risk of venous thromboembolism in users of hormone replacement therapy. Lancet, 348, 1996, s. 977-980.
8. Dulíček, P., Kalousek, I., Malý, J.: Hormonální antikoncepce a tromboembolická nemoc - jak je to ve skutečnosti. Interní medicína, 8, 2002, s. 6-9.
9. Dulíček, P., Malý, J., Šafářová, M.: Risk of thrombosis in patients homozygous and heterozygous for factor V Leiden in the East Bohemian Region. Clin. Appl. Thromb. Hemos., 6, 2000, s. 87-89.
10. Dulíček, P.: Hormonální antikoncepce a tromboembolická nemoc - patofyziologické poznatky a praktická doporučení. Čes. Gynek., 66, 2001, s. 363-368.
11. Endrikat, J., Noah, M., Gerllinger, C. et al.: Impact of oral contraceptive use on AOC-resistance: a prospective, randomized clinical trial with three low-dose preparations. Contraception, 64, 2001, s. 217-222.
12. Farmer, R. D. T., Lawrenson, R. A., Thompson, C. R., Kennedy, J. G., Hambleton, I. R.: Population-based study of risk of venous thromboembolism associated with various oral contraceptives. Lancet, 349, 1997, s. 83-88.
13. Farmer, R. D. T., Todd, J.-C., Lewis, M. A., MacRae, D. K., Williams, T. J.: The risk of venous thromboembolic disease among German women using oral contraceptives: a database study. Contraception, 57, 1998, s. 67-70.
14. Grodstein, F., Stampfer, M. J., Goldhaber, S. Z. et al.: Prospective study of exogenous hormones and risk of pulmonary embolism in women. Lancet, 348, 1996, s. 983-987.
15. Herings, R. M. C., Urquhart, J., Leufkens, H. G. M.: Venous thromboembolism among new users of different oral contraceptives. Lancet, 354, 1999, s. 127-128.
16. Hulley, S., Grady, D., Bush, T. et al.: Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. JAMA, 280, 1998, s. 605-613.
17. Jick, H., Derby, L. E., Wald Myers, M., Vasilakis, C., Newton, K. M.: Risk of hospital admission for idiopathic venous thromboembolism among users of postmenopausal oestrogens. Lancet, 348, 1996, s. 981-983.
18. Jick, H., Jick, S. S., Gurewich, V., Myers, M. W., Vasilakis, C.: Risk of idiopathic cardiovascular death and nonfatal venous thromboembolism in women using oral contraceptives with differing progestagen components. Lancet, 346, 1995, s. 1589-1593.
19. Jick, H., Kaye, J. A., Vasilakis-Scaramozze, C., Jick, S. S.: Risk of venous thromboembolism among users of third generation oral contraceptives compared with users of oral contraceptives with levonorgestrel before and after 1995: cohort and case-control analysis. BMJ, 321, 2000, s. 1190-1195.
20. Jordan, W. M.: Pulmonary embolism. Lancet, 2, 1961, s. 1146-1147.
21. Kvasnička, J.: Trombofilie, možnosti diagnostiky, prevence a léčby. Medica revue, 3, 1998, s. 7-10.
22. Lensing, A. W., Prandoni, P., Prins, M. H., Buller, H. R.: Deep-vein thrombosis. Lancet, 353, 1999, s. 479-485.
23. Lewis, M. A., MacRae, K. D., Kuhl-Habich, D., Bruppacher, R., Heinemann, L. A. J., Spitzer, W. O.: The differential risk of oral contraceptives: the impact of full exposure history. Hum. Reprod., 14, 1999, s. 1493-1499.
24. Lidegaard, O., Edstrom, B., Kreiner, S.: Oral contraceptives and venous thromboembolism. A case-control study. Contraception, 57, 1998, s. 291-301.
25. Lidegaard, O., Edstrom, B., Kreiner, S.: Oral contraceptives and venous thromboembolism: a five-year national case-control study. Contraception, 35, 2002, s. 187-196.
26. Matuška, J.: Antikoncepce a trombembolické příhody - lze cíleně omezovat riziko? Kapitoly z kardiologie, 3, 2002, nestr.
27. Parkim, L., Skegg, D. C. G., Wilson, M., Herbison, G. P., Paul, C.: Oral contraceptives and fatal pulmonary embolism. Lancet, 355, 2000, s. 2133-2134.
28. Paseka, J., Unzeitig, V., Cibula, D., Beliková, A., Matýšková, M., Chroust, K.: Leidenská mutace faktoru V u uživatelek hormonální antikoncepce. Čes. Gynek., 65, 2000, s. 156-159.
29. Rees, D. C., Cox, M., Clegg, J. B.: World distribution of factor V Leiden. Lancet, 346, 1995, s. 1133-1134.
30. Ridker, P. M., Miletich, J. P., Hennekens, C. H., Buring, J. E.: Ethnic distribution of factor V Leiden in 4047 men and women. JAMA, 277, 1997, s. 1305-1307.
31. Rodeghiero, F., Tosetto, A.: Activated protein C resistance and factor V Leiden mutation are independent risk factors for venous thromboembolism. Ann. Intern. Med., 130, 1999, s. 643-650.
32. Rosendaal, F. R., Helmerhorst, F. M., Vandenbroucke, J. P.: Female hormones and thrombosis. Arterioscler. Thromb. Vasc. Biol., 22, 2002, s. 201-210.
33. Seligsohn, U., Lubetsky, A.: Genetic susceptibility to venous thrombosis. N. Engl. J. Med., 344, 2001, s. 1222-1231.
34. Spitzer, W. O., Lewis, M. A., Heineman, L. A. J., Thorogood, M., MacRae, K. D.: Third generation oral contraceptives and risk of venous thromboembolic disorders: an international case-control study. BMJ, 312, 1996, s. 83-88.
35. Todd, J.-C., Lawrenson, R., Farmer, R. D. T., Williams, T. J., Leydon, G. M.: Venous thromboembolic disease and combined oral contraceptives: a re-analysis of the MediPlus database. Hum. Reprod., 14, 1999, s. 1500-1505.
36. Unzeitig, V., Paseka, J., Crha, I. et al.: Predikce rizika hluboké žilní trombózy při uživání hormonální kontracepce v gravidité. Závěrečná zpráva grantového úkolu 4079-3. IGA MU CR Praha, 2000, s. 101.
37. Unzeitig, V.: Hormonální antikoncepce a tromboembolická nemoc - nová epidemiologická data. Čes. Gynek., 66, 2001, s. 222-230.
38. Vandenbroucke, J. P., Koster, T., Briét, E., Reitsma, P. H., Bertina, R. M., Rosendaal, F. R.: Increased risk of venous thrombosis in oral-contraceptive users who are carriers of factor V Leiden mutation. Lancet, 344, 1994, s. 1453-1457.
39. Vandenbroucke, J. P., van der Meer, F. J. M., Helmerhorst, F. M., Rosendaal, F. R.: Factor V Leiden: should we screen oral contraceptive users and pregnant women? BMJ, 313, 1996, s. 1127-1130.
40. World Health Organization Collaborative Study on Cardiovascular Disease, and Steroid Hormone Contraception. Effect of different progestagens in low oestrogen oral contraceptives on venous thromboembolic disease. Lancet, 346, 1995, s. 1582-1588.